Lung Cancer Market, By Type (Non-Small Cell Lung Cancer (NSCLC) (Adenocarcinoma, Squamous Cell Carcinoma, and Large Cell Carcinoma), Small Cell Lung Cancer (SCLC), and Lung Carcinoid Tumor), By Drug Class (Cytotoxic Chemotherapy (Alkylating agents (cisplatin, carboplatin, etc.), Antimetabolites (pemetrexed, gemcitabine), Mitotic inhibitors (taxanes: paclitaxel, docetaxel), Topoisomerase inhibitors (etoposide, irinotecan), and Others), Targeted Therapy (EGFR Inhibitors (Erlotinib, etc.), ALK Inhibitors (Crizotinib, etc.), ROS1 Inhibitors (Entrectinib, etc.), BRAF/MEK Inhibitors (Dabrafenib, etc.), MET Inhibitors (Capmatinib, etc.), RET Inhibitors (Selpercatinib, etc.), HER2 Inhibitors (Trastuzumab, etc.)), Immunotherapy, (PD-1 Inhibitors (Nivolumab, etc.), PD-L1 Inhibitors (Atezolizumab, etc.), CTLA-4 Inhibitors (Ipilimumab, etc.)), and Other Combination Therapeutics) and Other Combination Therapeutics), By Molecule Type (Small Molecules and Biologics), By Route of Administration (Parenteral and Oral), By Stage of Disease (Early-stage (Stage I–II), Locally Advanced (Stage III), and Metastatic/Advanced (Stage IV)), By Age Group (Adult, Pediatric, and Geriatric), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Diagnostic Laboratories, Specialty Cancer Clinics, Homecare Settings, and Others (Research and Academic Institutes, etc.)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)